Clinical Trial Update: Risk-Guided Cardioprotection With Carvedilol in Breast Cancer Patients Treated With Doxorubicin and/or Trastuzumab [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating carvedilol for risk-guided cardioprotection in breast cancer patients receiving doxorubicin and/or trastuzumab; results have been poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Cardiomyopathy
• Cardiovascular Disease
• Heart Failure

Drugs mentioned

• Coreg (carvedilol)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Cardiotoxicity, Risk Factor, Cardiovascular | Phase 1 | Status: COMPLETED | Results posted: 2025-10-09